Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1994 1
1995 10
1996 4
1997 4
1998 2
1999 3
2000 3
2001 1
2002 2
2003 2
2005 4
2006 4
2008 1
2010 4
2013 2
2014 3
2015 2
2016 1
2017 4
2018 3
2019 4
2020 3
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
The risk of seizures among the carbapenems: a meta-analysis.
Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA. Cannon JP, et al. J Antimicrob Chemother. 2014 Aug;69(8):2043-55. doi: 10.1093/jac/dku111. Epub 2014 Apr 16. J Antimicrob Chemother. 2014. PMID: 24744302
In studies directly comparing imipenem and meropenem, there was no difference in epileptogenicity in either RD or pooled OR analyses. CONCLUSIONS: The absolute risk of seizures with carbapenems was low, albeit higher than with non-carbapenem antibiotics. Although …
In studies directly comparing imipenem and meropenem, there was no difference in epileptogenicity in either RD or pooled OR an …
Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections.
Edwards SJ, Emmas CE, Campbell HE. Edwards SJ, et al. Curr Med Res Opin. 2005 May;21(5):785-94. doi: 10.1185/030079905X46223. Curr Med Res Opin. 2005. PMID: 15969878 Review.
OBJECTIVE: To compare the effectiveness of meropenem with imipenem plus cilastatin in the treatment of severe infections. ...STUDY SELECTION: Randomized controlled trials of adult patients with severe infections treated with meropenem or imipenem plus …
OBJECTIVE: To compare the effectiveness of meropenem with imipenem plus cilastatin in the treatment of severe infections. ...S …
Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial.
Aguilar-Guisado M, Espigado I, Martín-Peña A, Gudiol C, Royo-Cebrecos C, Falantes J, Vázquez-López L, Montero MI, Rosso-Fernández C, de la Luz Martino M, Parody R, González-Campos J, Garzón-López S, Calderón-Cabrera C, Barba P, Rodríguez N, Rovira M, Montero-Mateos E, Carratalá J, Pérez-Simón JA, Cisneros JM. Aguilar-Guisado M, et al. Lancet Haematol. 2017 Dec;4(12):e573-e583. doi: 10.1016/S2352-3026(17)30211-9. Epub 2017 Nov 15. Lancet Haematol. 2017. PMID: 29153975 Clinical Trial.
EAT based on an antipseudomonal beta-lactam drug as monotherapy (ceftazidime or cefepime, meropenem or imipenem, or piperacillin-tazobactam) or as combination therapy (with an aminoglycoside, fluoroquinolone, or glycopeptide) was started according to local protocols …
EAT based on an antipseudomonal beta-lactam drug as monotherapy (ceftazidime or cefepime, meropenem or imipenem, or piperacill …
Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Brismar B, Malmborg AS, Tunevall G, Lindgren V, Bergman L, Mentzing LO, Nyström PO, Anséhn S, Bäckstrand B, Skau T, et al. Brismar B, et al. J Antimicrob Chemother. 1995 Jan;35(1):139-48. doi: 10.1093/jac/35.1.139. J Antimicrob Chemother. 1995. PMID: 7768761 Clinical Trial.
Seventy-five men and 57 women (mean age 51 years) were enrolled in the meropenem group and 67 men and 50 women (mean age 52 years) in the imipenem/cilastatin group. The patients received either meropenem, 500 mg q 8 h, or imipenem/cilastatin, 500 mg/50 …
Seventy-five men and 57 women (mean age 51 years) were enrolled in the meropenem group and 67 men and 50 women (mean age 52 years) in …
Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
Verwaest C; Belgian Multicenter Study Group. Verwaest C, et al. Clin Microbiol Infect. 2000 Jun;6(6):294-302. doi: 10.1046/j.1469-0691.2000.00082.x. Clin Microbiol Infect. 2000. PMID: 11168137 Free article. Clinical Trial.
OBJECTIVE: To compare the efficacy and tolerability of meropenem and imipenem/cilastatin as empirical monotherapy in intensive care unit (ICU) patients with serious bacterial infections. ...All five meropenem recipients with sepsis had a satisfactory clinical …
OBJECTIVE: To compare the efficacy and tolerability of meropenem and imipenem/cilastatin as empirical monotherapy in intensive …
Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
Nichols RL, Smith JW, Geckler RW, Wilson SE. Nichols RL, et al. South Med J. 1995 Apr;88(4):397-404. doi: 10.1097/00007611-199504000-00003. South Med J. 1995. PMID: 7716590 Clinical Trial.
In a multicenter, open-label, prospective trial, we compared the efficacy and safety of meropenem with imipenem/cilastatin in patients with skin and soft tissue infections. ...Meropenem was well tolerated and as effective as imipenem/cilastatin in trea …
In a multicenter, open-label, prospective trial, we compared the efficacy and safety of meropenem with imipenem/cilastatin in …
Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
Geroulanos SJ. Geroulanos SJ. J Antimicrob Chemother. 1995 Jul;36 Suppl A:191-205. doi: 10.1093/jac/36.suppl_a.191. J Antimicrob Chemother. 1995. PMID: 8543495 Clinical Trial.
At the end of therapy, a satisfactory clinical response (cure or improvement) was seen in 79/82 (96%) evaluable meropenem patients and 83/88 (94%) imipenem/cilastatin patients; this was still seen at follow-up (57/63; 90% and 58/66; 88%, respectively). ...The result …
At the end of therapy, a satisfactory clinical response (cure or improvement) was seen in 79/82 (96%) evaluable meropenem patients an …
Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
Nakane T, Tamura K, Hino M, Tamaki T, Yoshida I, Fukushima T, Tatsumi Y, Nakagawa Y, Hatanaka K, Takahashi T, Akiyama N, Tanimoto M, Ohyashiki K, Urabe A, Masaoka T, Kanamaru A; Japan Febrile Neutropenia Study Group. Nakane T, et al. J Infect Chemother. 2015 Jan;21(1):16-22. doi: 10.1016/j.jiac.2014.08.026. Epub 2014 Sep 17. J Infect Chemother. 2015. PMID: 25239059 Clinical Trial.
We conducted an open-label, randomized study to evaluate the clinical efficacy of cefozopran, meropenem or imipenem-cilastatin using cefepime as a control in febrile neutropenia (FN) patients. Three hundred and seventy-six patients received cefepime, cefozopran, …
We conducted an open-label, randomized study to evaluate the clinical efficacy of cefozopran, meropenem or imipenem-cilastatin …
Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
Kuo BI, Fung CP, Liu CY. Kuo BI, et al. Zhonghua Yi Xue Za Zhi (Taipei). 2000 May;63(5):361-7. Zhonghua Yi Xue Za Zhi (Taipei). 2000. PMID: 10862445 Clinical Trial.
BACKGROUND: Meropenem and imipenem are beta-lactam antibiotics of the carbapenem group. ...Satisfactory clinical outcome (excellent and good) was 84% in the meropenem group and 76% in the imipenem/cilastatin group. Satisfactory bacteriologic response w …
BACKGROUND: Meropenem and imipenem are beta-lactam antibiotics of the carbapenem group. ...Satisfactory clinical outcome (exce …
Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.
Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR. Novelli A, et al. Clin Pharmacokinet. 2005;44(5):539-49. doi: 10.2165/00003088-200544050-00007. Clin Pharmacokinet. 2005. PMID: 15871639 Clinical Trial.
Patients were divided into two groups: group I received intravenous imipenem 1g plus cilastatin 1g, and group II received intravenous meropenem 1g over 30 minutes. ...CONCLUSION: The more favourable pharmacokinetic profile of imipenem compared with meropen …
Patients were divided into two groups: group I received intravenous imipenem 1g plus cilastatin 1g, and group II received intravenous …
74 results